Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG.

ABSTRACT:

Objective

Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relatively short half-life, lecanemab administered as a bi-monthly infusion (typically 10 mg/kg) has a relatively brief half-life. Interaction with abundant plasma proteins binder in the bloodstream can affect pharmacokinetics of drugs, including their half-life. In this study, we investigated potential plasma protein binding (PPB) interaction to lecanemab using lecanemab biosimilar.

Methods

Lecanemab biosimilar used in this study was based on publicly available sequences. ELISA and western blotting were used to assess lecanemab biosimilar immunoreactivity in the fractions of hum

SUBMITTER: Bellier JP 

PROVIDER: S-EPMC11651182 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature